Choice A rationale
Heart rate is an important vital sign to monitor in patients, but it is not the primary outcome
data to prioritize when administering a 20% mannitol intravenous (IV) solution. Mannitol is a diuretic that works by increasing the amount of urine produced. Therefore, while heart rate can be affected by fluid balance changes, it is not the most directly relevant outcome to monitor in this context.
Choice B rationale
Ankle circumference could be an indicator of peripheral edema, which might suggest fluid
overload or poor kidney function. However, in the context of mannitol administration, which is a diuretic and would be expected to decrease fluid overload, ankle circumference is not the primary outcome to monitor.
Choice C rationale
Urinary output is the correct answer. Mannitol is an osmotic diuretic that increases urine
production. It is used to reduce intracranial and intraocular pressure by drawing water out of tissues and into the bloodstream, from where it can be excreted by the kidneys. Therefore, urinary output is the most direct measure of its effectiveness and is the key outcome that should be monitored.
Choice D rationale
Dietary intake is always important to monitor in patients, especially those receiving IV
therapy, as it can impact electrolyte balance and overall health status. However, it is not the primary outcome to monitor when administering mannitol.

Choice A rationale
Clearing the nose with a tissue prior to the instillation of nasal drops can help to remove
mucus and other obstructions, allowing the medication to reach the nasal passages more
effectively15.
Choice B rationale
Deep inhalation through the nose is not typically recommended prior to the instillation of
nasal drops. It could potentially draw the medication deeper into the nasal passages or into the
throat, rather than allowing it to remain in the intended area15.
Choice C rationale
Holding the breath temporarily is not typically necessary or recommended prior to the
instillation of nasal drops15.
Choice D rationale